EyeYon Medical Overview
EyeYon Medical is a start-up company specializing in developing medical ophthalmic devices for complications resulting from various corneal diseases, including corneal edema. EyeYon Medical has developed exclusive technologies that have proven to have a solution to acute problems in the ophthalmic world. EyeYon Medical's flagship product is an artificial endothelial layer called EndoArt. EndoArt is a synthetic implant attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction. The minimally invasive EndoArt is designed to replace dysfunctional endothelium to cure corneal edema, offering a safe and simple solution that will be available to anyone, anywhere. EyeYon Medical also developed the Hyper CL, an FDA-approved therapeutic contact lens for a variety of corneal conditions that require eye drop treatment.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- EyeYon Medical is proud to announce its expansion in China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co.,...
EyeYon Medical has announced its expansion into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co., Ltd. This strategic move aims to address unmet needs in Chinas ophthalmology sector, particularly focusing on corneal blindness. The expansion is expected to accelerate EyeYons growth trajectory by allowing the company to better serve Chinese patients and healthcare providers. The subsidiary will focus on product localization, strategic partnerships, clinical studies, regulatory compliance, and talent acquisition. EyeYon Medical is committed to integrating its technologies into the Chinese healthcare system and supporting local communities through educational and philanthropic activities. The companys EndoArt, a synthetic corneal implant, is highlighted as a groundbreaking alternative to donor tissue.
ExpandPartnersProduct Stage
growth-positive
EyeYon Medical Appoints Dr. Sharon Bakalash MD, PhD As Chief Medical Officer
EyeYon Medical announces the appointment of Dr. Sharon Bakalash as Chief Medical Officer. Dr. Bakalash brings extensive experience in clinical development and medical affairs to the company. She will lead the clinical activity for EyeYon Medicals innovative products, including the EndoArt synthetic corneal endothelium and the HyperCL contact lens. The CEO of EyeYon Medical, Nahum Ferera, expresses his excitement about having Dr. Bakalash as a leader for the companys global clinical activity. Dr. Bakalash has a strong background in the ophthalmic space, having worked with biotechnology companies and served as a chief medical officer in the industry. She holds an MD, a PhD, and a business degree.
Management Changes
growth-positive
Israel's EyeYon Medical Receives CE Mark For Its Synthetic Implant
Israeli startup EyeYon Medical has received a CE Mark for its EndoArt implant, a synthetic implant that replaces the human endothelium to treat chronic corneal edema. The implant eliminates the need for corneal donations and offers a minimally invasive surgery option. EyeYon Medical has also raised $25 million, bringing its total capital raised to $36 million. The company plans to work closely with healthcare providers in Europe to provide the innovative solution to patients suffering from corneal edema.
CustomersInvestment
growth-positive
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China
EyeYon Medicals EndoArt® has been granted the Innovative Device Status by Chinas Center for Medical Device Evaluation. It is the only ophthalmic device in the world to receive both Chinas Innovative Device Status and the Breakthrough Device Designation from the U.S. FDA. EndoArt® is a synthetic implant that treats chronic corneal edema, reducing the need for human donor tissue. The company has conducted clinical trials in Europe, India, and Israel, showing significant reduction in edema. EyeYon Medical plans to begin its first in-human trial in China soon. The companys investors, including Rimonci Capital, are supporting its technology advancement in China.
PartnersInvestment
growth-positive
EyeYon Medical raises $25 million for corneal implants
Israeli life sciences company EyeYon Medical has raised $25 million in a series C investment round. The funds will be used to expand the clinical trials of its flagship product, the EndoArt, a synthetic implant that treats chronic corneal edema. The implant eliminates the need for human tissue or corneal donations. EyeYon Medical aims to simplify corneal surgical procedures and address the long waiting list for available human donor corneas. The companys technology has already shown safety and efficacy in human trials. The funding round reflects investor confidence in the companys unique and disruptive technology.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $36.14M |
| Last funding | $25M |
| Stage | C |
| Rounds | 4 |
| Investors | 12 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | eye-yon.com |
Locations
5 Golda Meir St., Ness Ziona, Israel
Photos & Videos
4 item(s)
